Sort
10,766 grants matching “checkpoint inhibitor”
Characterizing and Targeting BAX- and BAK-Dependent Cell Death in Cancer
$487,929Emily H Cheng · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
Project 1: Evaluating stem-like T cells and improving efficacy of checkpoint inhibitors in NSCLC
$487,846Rafi Ahmed · Emory University · P50 · FY2021 · CA
Gemcitabine-Radiation for Advanced Pancreatic Cancer
$487,829Theodore S Lawrence · University Of Michigan At Ann Arbor · R01 · FY2009 · CA
Project 1: Investigation of immune and stromal factors that promote prostate adenocarcinoma progression and castration response
$487,709Charles L Sawyers · Columbia University Health Sciences · P01 · FY2025 · CA
Reprogramming Exosomes for Novel Immunotherapy of Triple Negative Breast Cancer
$487,588Yong Zhang · University Of Southern California · R01 · FY2024 · CA
Defining the role of NF1 and SPRED1 loss in melanoma
$487,530Iwei Yeh · University Of California, San Francisco · R37 · FY2023 · CA
Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer
$487,506Kent W Mouw · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC
$487,476Judith A. Varner · University Of California, San Diego · R01 · FY2018 · CA
Exploring palmitoylation dynamics: impacts on Cadherin-Catenin adhesion and lipid metabolism in the progression of melanoma lung metastasis
$487,468Shuyang Chen · Cleveland Clinic Lerner Com-Cwru · R37 · FY2025 · CA
Intrinsic B cell epigenetic regulation of antibody and autoantibody responses by Sirt1
$487,376Paolo Casali · University Of Texas Hlth Science Center · R01 · FY2019 · AI
IDO1 and Immunotolerance in Glioblastoma
$487,318Derek Alan Wainwright · Loyola University Chicago · R01 · FY2024 · NS
Project 3: Exploit Immune Consequences of U1 Mutations in Sonic Hedgehog (Shh) Medulloblastoma
$487,130Nazanin Koohbanani Majd · University Of Tx Md Anderson Can Ctr · P50 · FY2025 · CA
Acute Kidney Injury and Double Negative T Cells
$486,804Abdel Hamad · Johns Hopkins University · R01 · FY2023 · DK
Immunometabolic pathways enabled by PARP inhibition in breast cancer
$486,593Jennifer L. Guerriero · Brigham And Women'S Hospital · R37 · FY2025 · CA
Tumor cell metabolism in action
$486,290Eileen White · Rutgers Biomedical And Health Sciences · R01 · FY2025 · CA
Project-003
$486,160Ryan Bruce Corcoran · Massachusetts General Hospital · U54 · FY2021 · CA
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer
$486,085Lily Yang · Emory University · R01 · FY2021 · CA
ENHANCING IMMUNE CHECKPOINT INHIBITOR THERAPY IN KIDNEY CANCER
$486,000The University Of Texas Southwestern Medical Center · · FY2015 · Department of the Army
Transcriptional Control of Natural Killer Cell Development
$486,000Barbara Lynne Kee · University Of Chicago · R01 · FY2022 · AI
Transcriptional Control of Natural Killer Cell Development
$486,000Barbara Lynne Kee · University Of Chicago · R01 · FY2023 · AI
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma
$485,968Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma
$485,760Yi Lin · Mayo Clinic Rochester · R01 · FY2022 · CA
Evaluation of Immune-based Combinations in Prostate Cancer
$485,739Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
$485,407Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2021 · CA
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
$485,407Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2020 · CA